Biotechnology Value Fund L P - Net Worth and Insider Trading

Biotechnology Value Fund L P Net Worth

The estimated net worth of Biotechnology Value Fund L P is at least $1.0 Billion dollars as of 2024-03-03. Biotechnology Value Fund L P is the of Kymera Therapeutics Inc and owns about 5,054,898 shares of Kymera Therapeutics Inc (KYMR) stock worth over $220 Million. Biotechnology Value Fund L P is the of Xenon Pharmaceuticals Inc and owns about 3,049,626 shares of Xenon Pharmaceuticals Inc (XENE) stock worth over $143 Million. Biotechnology Value Fund L P is also the of Cullinan Oncology Inc and owns about 7,415,823 shares of Cullinan Oncology Inc (CGEM) stock worth over $137 Million. Besides these, Biotechnology Value Fund L P also holds Olema Pharmaceuticals inc (OLMA) , XOMA Corp (XOMA) , Repare Therapeutics Inc (RPTX) , ChemoCentryx Inc (CCXI) , Third Harmonic Bio Inc (THRD) , Cytokinetics Inc (CYTK) , CTI BioPharma Corp (CTIC) , Alpine Immune Sciences Inc (ALPN) , Arqule Inc (ARQL) , Merus NV (MRUS) , IDEAYA Biosciences Inc (IDYA) , Eledon Pharmaceuticals Inc (ELDN) , Rain Oncology Inc (RAIN) , Five Prime Therapeutics Inc (FPRX) , Immune Design Corp (IMDZ) , GlycoMimetics Inc (GLYC) , Concert Pharmaceuticals Inc (CNCE) , Pieris Pharmaceuticals Inc (PIRS) , Capstone Holding Corp (CAPS) , Calithera Biosciences Inc (CALA) , Infinity Pharmaceuticals Inc (INFIQ) , POINT Biopharma Global Inc (PNT) . Details can be seen in Biotechnology Value Fund L P's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Biotechnology Value Fund L P has not made any transactions after 2023-12-18 and currently still holds the listed stock(s).

Transaction Summary of Biotechnology Value Fund L P

To

Biotechnology Value Fund L P Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Biotechnology Value Fund L P owns 52 companies in total, including Five Prime Therapeutics Inc () , Eledon Pharmaceuticals Inc () , and XOMA Corp () among others .

Click here to see the complete history of Biotechnology Value Fund L P’s form 4 insider trades.

Insider Ownership Summary of Biotechnology Value Fund L P

Ticker Comapny Transaction Date Type of Owner
Five Prime Therapeutics Inc 2020-11-11 10 percent owner
Eledon Pharmaceuticals Inc 2023-05-05 other: See Explanation of Responses
XOMA Corp 2023-01-06 other: See Explanation of Responses
Merus NV 2021-10-08 other: See Explanation of Responses
Kymera Therapeutics Inc 2023-11-03 other: See Explanation of Responses
Principia Biopharma Inc 2020-08-18 other: See Explanation of Responses
IDEAYA Biosciences Inc 2021-02-02 other: See Explanation of Responses
Calithera Biosciences Inc 2020-05-21 other: See Explanation of Responses
CTI BioPharma Corp 2022-08-09 other: See Explanation of Responses
Cytokinetics Inc 2020-12-09 other: See Explanation of Responses
Pieris Pharmaceuticals Inc 2019-09-06 other: See Explanation of Responses
GlycoMimetics Inc 2020-11-04 other: See Explanation of Responses
Concert Pharmaceuticals Inc 2019-06-10 other: See Explanation of Responses
Infinity Pharmaceuticals Inc 2021-02-11 other: See Explanation of Responses
Immune Design Corp 2018-12-04 other: See Explanation of Responses
Syndax Pharmaceuticals Inc 2017-11-28 other: See Explanation of Responses
Arqule Inc 2018-05-30 other: See Explanation of Responses
Xenon Pharmaceuticals Inc 2017-08-15 other: See Explanation of Responses
Regulus Therapeutics Inc 2017-11-17 other: See Explanation of Responses
Capstone Holding Corp 2017-07-14 10 percent owner & other: Direct Beneficial Owner
Alpine Immune Sciences Inc 2017-06-20 other: See Explanation of Responses
Cascadian Therapeutics Inc 2016-06-23 10 percent owner
ChemoCentryx Inc 2015-11-04 other: See Explanation of Responses
Catalyst Biosciences Inc 2009-07-09 other: Direct Beneficial Owner
Ligand Pharmaceuticals Inc 2008-11-06 10 percent owner & other: Direct Beneficial Owners
Regado Biosciences Inc 2014-03-21 other: See Explanation of Responses
Palatin Technologies Inc 2011-10-05 other: See Explanation of Responses
Rigel Pharmaceuticals Inc 2013-05-01 other: See Explanation of Responses
Neurocrine Biosciences Inc 2008-02-20 10 percent owner & other: Direct Beneficial Owner
EPIRUS Biopharmaceuticals Inc 2009-12-22 other: Direct Beneficial Owner
MediciNova Inc 2009-12-18 10 percent owner
Neurobiological Technologies Inc 2009-10-21 other: Direct Beneficial Owner
Dynavax Technologies Corp 2008-10-23 10 percent owner & other: Indirect Beneficial Owners
Repligen Corp 2009-05-15 10 percent owner & other: Group Member
Curis Inc 2009-02-03 10 percent owner & other: Indirect Beneficial Owners
Aeolus Pharmaceuticals Inc 2006-06-06 10 percent owner & other: Indirect Beneficial Owner
AMAG Pharmaceuticals Inc 2006-01-12 other: Direct Beneficial Owner
Arena Pharmaceuticals Inc 2004-07-07 other: Direct Beneficial Owner
BioCryst Pharmaceuticals Inc 2003-10-27 other: Direct Beneficial Owner
XOMA Corp 2017-02-10 other: See Explanation of Responses
CytomX Therapeutics Inc 2020-12-18 other: See Explanation of Responses
Verastem Inc 2022-01-25 other: See Explanation of Responses
Rain Oncology Inc 2022-11-08 other: See Explanation of Responses
Olema Pharmaceuticals inc 2023-09-12 10 percent owner
Cullinan Oncology Inc 2022-06-01 other: See Explanation of Responses
Repare Therapeutics Inc 2023-11-16 other: See Explanation of Responses
MoonLake Immunotherapeutics 2022-04-05 director & 10 percent owner
4D Molecular Therapeutics Inc 2022-06-16 other: See Explanation of Responses
ESSA Pharma Inc 2022-07-11 10 percent owner
Third Harmonic Bio Inc 2022-12-20 other: See Explanation of Responses
Structure Therapeutics Inc 2023-02-03 other: See Explanation of Responses
POINT Biopharma Global Inc 2023-12-18 other: See Explanation of Responses

Biotechnology Value Fund L P Latest Holdings Summary

Biotechnology Value Fund L P currently owns a total of 25 stocks. Among these stocks, Biotechnology Value Fund L P owns 5,054,898 shares of Kymera Therapeutics Inc (KYMR) as of November 3, 2023, with a value of $220 Million and a weighting of 21.22%. Biotechnology Value Fund L P owns 3,049,626 shares of Xenon Pharmaceuticals Inc (XENE) as of August 15, 2017, with a value of $143 Million and a weighting of 13.8%. Biotechnology Value Fund L P also owns 7,415,823 shares of Cullinan Oncology Inc (CGEM) as of June 1, 2022, with a value of $137 Million and a weighting of 13.25%. The other 22 stocks Olema Pharmaceuticals inc (OLMA) , XOMA Corp (XOMA) , Repare Therapeutics Inc (RPTX) , ChemoCentryx Inc (CCXI) , Third Harmonic Bio Inc (THRD) , Cytokinetics Inc (CYTK) , CTI BioPharma Corp (CTIC) , Alpine Immune Sciences Inc (ALPN) , Arqule Inc (ARQL) , Merus NV (MRUS) , IDEAYA Biosciences Inc (IDYA) , Eledon Pharmaceuticals Inc (ELDN) , Rain Oncology Inc (RAIN) , Five Prime Therapeutics Inc (FPRX) , Immune Design Corp (IMDZ) , GlycoMimetics Inc (GLYC) , Concert Pharmaceuticals Inc (CNCE) , Pieris Pharmaceuticals Inc (PIRS) , Capstone Holding Corp (CAPS) , Calithera Biosciences Inc (CALA) , Infinity Pharmaceuticals Inc (INFIQ) , POINT Biopharma Global Inc (PNT) have a combined weighting of 51.73% among all his current holdings.

Latest Holdings of Biotechnology Value Fund L P

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
KYMR Kymera Therapeutics Inc 2023-11-03 5,054,898 43.50 219,888,063
XENE Xenon Pharmaceuticals Inc 2017-08-15 3,049,626 46.90 143,027,459
CGEM Cullinan Oncology Inc 2022-06-01 7,415,823 18.51 137,266,884
OLMA Olema Pharmaceuticals inc 2023-09-12 8,897,173 14.80 131,678,160
XOMA XOMA Corp 2023-01-06 3,645,542 24.77 90,300,075
RPTX Repare Therapeutics Inc 2023-11-16 10,166,943 7.20 73,201,990
CCXI ChemoCentryx Inc 2015-11-04 1,251,914 51.99 65,087,009
THRD Third Harmonic Bio Inc 2022-12-20 4,338,167 10.32 44,765,545
CYTK Cytokinetics Inc 2020-12-09 463,244 73.98 34,270,791
CTIC CTI BioPharma Corp 2022-08-09 2,271,791 9.09 20,650,580
ALPN Alpine Immune Sciences Inc 2017-06-20 507,040 36.00 18,253,440
ARQL Arqule Inc 2018-05-30 771,305 20.00 15,426,100
MRUS Merus NV 2021-10-08 232,747 51.83 12,063,277
IDYA IDEAYA Biosciences Inc 2021-02-02 233,150 46.21 10,773,862
ELDN Eledon Pharmaceuticals Inc 2023-05-05 4,288,005 1.61 6,903,688
RAIN Rain Oncology Inc 2022-11-08 3,288,186 1.21 3,978,705
FPRX Five Prime Therapeutics Inc 2020-11-11 81,263 38.00 3,087,994
IMDZ Immune Design Corp 2018-12-04 370,391 5.85 2,166,787
GLYC GlycoMimetics Inc 2020-11-04 630,453 3.00 1,891,359
CNCE Concert Pharmaceuticals Inc 2019-06-10 169,589 8.37 1,419,460
PIRS Pieris Pharmaceuticals Inc 2019-09-06 314,139 0.17 54,346
CAPS Capstone Holding Corp 2017-07-14 2,268 7.00 15,876
CALA Calithera Biosciences Inc 2020-05-21 24,022 0.02 480
INFIQ Infinity Pharmaceuticals Inc 2021-02-11 534,847 0.00 53
PNT POINT Biopharma Global Inc 2023-12-18 0 12.50 0

Holding Weightings of Biotechnology Value Fund L P


Biotechnology Value Fund L P Form 4 Trading Tracker

According to the SEC Form 4 filings, Biotechnology Value Fund L P has made a total of 8 transactions in Kymera Therapeutics Inc (KYMR) over the past 5 years, including 8 buys and 0 sells. The most-recent trade in Kymera Therapeutics Inc is the acquisition of 414,105 shares on November 3, 2023, which cost Biotechnology Value Fund L P around $5 Million.

According to the SEC Form 4 filings, Biotechnology Value Fund L P has made a total of 0 transactions in Xenon Pharmaceuticals Inc (XENE) over the past 5 years. The most-recent trade in Xenon Pharmaceuticals Inc is the acquisition of 60,202 shares on August 15, 2017, which cost Biotechnology Value Fund L P around $157,127.

According to the SEC Form 4 filings, Biotechnology Value Fund L P has made a total of 3 transactions in Cullinan Oncology Inc (CGEM) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Cullinan Oncology Inc is the acquisition of 751,396 shares on June 1, 2022, which cost Biotechnology Value Fund L P around $8 Million.

More details on Biotechnology Value Fund L P's insider transactions can be found in the Insider Trading History of Biotechnology Value Fund L P table.

Insider Trading History of Biotechnology Value Fund L P

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Biotechnology Value Fund L P Trading Performance

GuruFocus tracks the stock performance after each of Biotechnology Value Fund L P's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Biotechnology Value Fund L P is 30.17%. GuruFocus also compares Biotechnology Value Fund L P's trading performance to market benchmark return within the same time period. The performance of stocks bought by Biotechnology Value Fund L P within 3 months outperforms 55 times out of 106 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Biotechnology Value Fund L P's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Biotechnology Value Fund L P

Average Relative Return

44.18%

Average relative return per transaction

Outperforming Transactions

62%

61 out of 98 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) 11.16 30.17 34.13 44.18 4.16 4.07
Relative Return to S&P 500(%) 10.08 25.65 27.5 28.43 -6.9 -7.84

Biotechnology Value Fund L P Ownership Network

Ownership Network List of Biotechnology Value Fund L P

No Data

Ownership Network Relation of Biotechnology Value Fund L P


Biotechnology Value Fund L P Owned Company Details

What does Five Prime Therapeutics Inc do?

Who are the key executives at Five Prime Therapeutics Inc?

Biotechnology Value Fund L P is the 10 percent owner of Five Prime Therapeutics Inc. Other key executives at Five Prime Therapeutics Inc include 10 percent owner Bvf Partners L P/il , 10 percent owner Bvf Inc/il , and other: See Explanation of Responses Biotechnology Value Fund Ii Lp .

Five Prime Therapeutics Inc () Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Five Prime Therapeutics Inc () in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Five Prime Therapeutics Inc () were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Five Prime Therapeutics Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Five Prime Therapeutics Inc Insider Transactions

No Available Data

Biotechnology Value Fund L P Mailing Address

Above is the net worth, insider trading, and ownership report for Biotechnology Value Fund L P. You might contact Biotechnology Value Fund L P via mailing address: 44 Montgomery Street, 40th Fl, San Francisco Ca 94104.

Discussions on Biotechnology Value Fund L P

No discussions yet.